Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Restasis ophthalmic emulsion | Cyclosporine | Dry eye disease | Do not list | Complete | ||
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
| Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revlimid | Lenalidomide | Multiple Myeloma, newly diagnosed | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revlimid | Lenalidomide | Multiple Myeloma (+bortezomib+dex) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
| Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | ||
| Revolade | eltrombopag | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Rexulti | Brexpiprazole | schizophrenia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Psoriatic Arthritis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024